From: The genetic basis for inactivation of Wnt pathway in human osteosarcoma
N | Disease free survival | Overall survival | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
P | HR | 95.0% CI | P | HR | 95.0% CI | |||||
L | U | L | U | |||||||
Sex | Male | 29 | 0.86 | 0.07* | ||||||
Female | 29 | 0.86 | 1.11 | 0.36 | 3.44 | 0.08 | 3.49 | 0.86 | 14.28 | |
Age group | <=15 y | 14 | 0.76 | 0.79 | ||||||
15-20 y | 23 | 0.94 | 1.10E + 04 | 0 | 1.40E + 116 | 0.5 | 1.82 | 0.32 | 10.42 | |
21-30 y | 11 | 0.94 | 3.70E + 04 | 0 | 4.40E + 116 | 0.72 | 0.73 | 0.13 | 4.05 | |
31-40 y | 1 | 0.93 | 5.30E + 04 | 0 | 6.40E + 116 | 0.97 | 0 | 0 | 1.90E + 282 | |
>40 y | 9 | 1 | 1.02 | 0 | 3.90E + 225 | 0.99 | 0 | 0 | ||
Tumor location | limbs | 51 | 0.28 | 0.97 | ||||||
Others | 7 | 0.48 | 23.34 | 0.004 | 1.60E + 05 | 0.97 | 0.97 | 0.12 | 7.72 | |
Enneking stage | I | 4 | 0.96 | 0.43 | ||||||
IIA | 19 | 0.78 | 0.71 | 0.06 | 7.88 | 0.17 | 0.1 | 0.004 | 2.74 | |
IIB | 2 | 0.631 | 0.59 | 0.07 | 5.01 | 0.1 | 0.09 | 0.01 | 1.61 | |
III | 1 | 0.897 | 0.83 | 0.05 | 13.39 | 0.99 | 0 | 0 | ||
Neoadjuvant chemotherapy | No | 10 | 0.51 | 1.5E-4* | ||||||
Yes | 30 | 0.51 | 1.51 | 0.44 | 5.15 | 0.003 | 11.85 | 2.36 | 59.45 | |
Adjuvant chemotherapy | No | 3 | 0.21 | 0.41 | ||||||
Yes | 19 | 0.43 | 0.04 | 0 | 129.34 | 0.61 | 0.04 | 0 | 1.20E + 04 | |
Recurrence | No | 50 | 0.49 | |||||||
Yes | 8 | 0.49 | 2.05 | 0.26 | 16.26 | |||||
Metastasis | No | 38 | 0.045* | |||||||
Yes | 11 | 0.436 | 0.01 | 0 | 2.40E + 03 |